Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph not_applicable
2
50%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (50.0%)
N/A2 (50.0%)

Trials by Status

unknown125%
completed250%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

NCT01620216
completednot_applicable

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

NCT01872819
unknownphase_2

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

NCT00003253
completednot_applicable

Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer

NCT00305617

Clinical Trials (4)

Showing 4 of 4 trials
NCT01620216Phase 2

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Terminated
NCT01872819Not Applicable

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Completed
NCT00003253Phase 2

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

Unknown
NCT00305617Not Applicable

Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4